Clinical Trial Update: TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

View source ↗

Summary

A post-marketing study in Japan is evaluating tezepelumab (TEZSPIRE) for severe or intractable bronchial asthma. The study is currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Asthma

Drugs mentioned

• Tezspire (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy) | Status: ACTIVE_NOT_RECRUITING